Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The weight-loss drug, following regulatory approval late last year, brought in $175 million in revenue in just its first few weeks on the market. Doctors and their patients are flocking to weight-loss drugs known as GLP-1 agonists, and demand has even surpassed supply. (Lilly's drug actually is a dual GLP-1/GIP receptor agonist, acting on two pathways involved in digestion instead of just one. Both types of treatments help regulate blood sugar levels and appetite.) The market for obesity drugs may reach more than $100 billion by 2030, up by 16 times from today, according to Goldman Sachs Research. But one element could get in the way of this spectacular growth story, and that's the fact that Medicare won't reimburse these drugs for weight loss alone. The agency will only offer reimbursement if the drug is also approved and prescribed for a medical condition it covers. This is a hurdle for many patients, who can't afford the $1,059 list price for a one-month supply of Zepbound. Rec
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Analyst unveils Amgen stock price target after weight-loss drug data [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and Wegovy [Yahoo! Finance]Yahoo! Finance
- 25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says [FOX Business Network]FOX Business Network
- Here Comes Obesity Drug Competition: Amgen Shares Soar On "Very Encouraging" Clinical Trial Update [zero hedge]zero hedge
- How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand' for weight-loss drugs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 5/3/24 - Form SD
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- LLY's page on the SEC website